Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

By M. Seymour, T. Maughan, Jonathan A. Ledermann, C. Topham, R. James, S. Gwyther, David B. Smith, S. Shepherd, A. Maraveyas, D. Ferry and 5 more. The Lancet, 2007

598 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/523d085f366df4845bce0505c05659d4dcd733d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Cutsem
2. A. Cervantes
3. D. Arnold
4. P. Quirke
5. Sung‐Liang Yu
6. B. Nordlinger
7. I. Nagtegaal
8. Hsuan-Yu Chen

Citations in the corpus

• MicroRNA signature predicts survival and relapse in lung cancer. (2008, methodology): “To seek statistical evidence for supporting the one-sided hypothesis that the high risk score of microRNA signature can predict poor survival in NSCLC patients, the combined samples of testing set and independent cohort were analyzed with the one-sided log-rank test (Flanigan et al., 2001; Seymour e”
• Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies (2014, background): “NCT00208546), COIN (ISRCTN 27286448) and FOCUS (ISRCTN 79877428), of which the results have been published previously.(17-21) Collection of formalin-fixed paraffin-embedded material (FFPE) of the primary tumor was part of the initial protocol in all four studies.”
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “There is evidence that FOLFIRI has a better therapeutic index in second-line compared with irinotecan monotherapy, also because there are clear safety advantages of FOLFIRI compared with irinotecan q 3 weekly [9] [I, B].”